10th Jul 2020 13:00
10 July 2020
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
U.S. Subsidiary Change of Name
Hemogenyx Pharmaceuticals plc is pleased to announce that its U.S. subsidiary will be renamed Hemogenyx Pharmaceuticals LLC in order to align the Company's names across entities and countries, and should always be referred to as Hemogenyx Pharmaceuticals instead of Hemogenyx by itself. The company will continue to conduct preclinical and clinical stage research and development activities to develop its own products and therapies, including therapies and treatments for blood and autoimmune diseases and viral infections. Hemogenyx Pharmaceuticals LLC will remain located at its state-of-the-art research facility in New York City.
Enquiries:
Hemogenyx Pharmaceuticals plc | https://hemogenyx.com |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Soltan Tagiev | |
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow | |
US Media enquiries | Tel: +1 (323) 646-3249 |
Lowell Goodman |
Related Shares:
Hemogenyx